Cefixime Capsules

Cefixime is a third-generation oral cephalosporin that kills bacteria by inhibiting bacterial cell wall synthesis. It is stable to most β-lactamases, and many penicillinase- and cephalosporinase-producing strains are still sensitive to this product. Cefixime has good antibacterial effects in vitro and in vivo against Gram-positive cocci such as pneumococci and Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). Cefixime also has antibacterial activity in vitro against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate.

The main ingredient of this product is cefixime.

This product is a hard capsule. After removing the capsule, the contents are white or light yellow powder.

This product is suitable for pharyngitis, tonsillitis, acute bronchitis and acute exacerbation of chronic bronchitis, otitis media, urinary tract infection, simple gonorrhea (cervicitis or urethritis) caused by sensitive bacteria.

Adults take 400 mg per day, and children take 8 mg/kg per day, either orally in a single dose or in two divided doses. Children weighing ≥50 kg or aged ≥12 years should use the adult dose. A single dose of 400 mg is appropriate for the treatment of simple gonorrhea. A single dose of 400 mg is appropriate for the treatment of simple gonorrhea. Patients with renal insufficiency whose creatinine clearance (CCr) is 21-60 ml/min and who undergo hemodialysis should be given 50% of the standard dose, i.e., 300 mg per day; patients with CCr ≤20 ml/min and who undergo peritoneal dialysis should be given 50% of the standard dose, i.e., 200 mg per day.

Most of the adverse reactions of cefixime are short-lived and mild. The most common are gastrointestinal reactions, including diarrhea (16%), increased bowel movement (6%), abdominal pain (3%), nausea (7%), indigestion (3%), and abdominal distension (4%); adverse reactions with an incidence rate of less than 2% include rash, urticaria, drug fever, itching, headache, and dizziness. Laboratory abnormalities include transient increases in ALT, AST, ALP, LDH, bilirubin, BUN, and Cr, transient decreases in platelet and white blood cell counts and eosinophilia, and positive direct Coombs test.

Patients with a history of allergy to this product or cephalosporin antibiotics are contraindicated.

Precautions for children: Use with caution in newborns and premature infants. Precautions for pregnancy and lactation: Use with caution in pregnant and lactating women. Precautions for the elderly: Use with caution in elderly patients.

(1) This product is contraindicated with the following drugs: amikacin sulfate, gentamicin, kanamycin, tobramycin. Neomycin, chlortetracycline hydrochloride, tetracycline hydrochloride, oxytetracycline hydrochloride, colistin sodium methanesulfonate, polymyxin B sulfate, erythromycin gluconate, erythromycin lactobionate, lincomycin, sulfisoxazole, aminophylline, soluble barbiturates, calcium chloride, calcium gluconate, other antihistamines such as diphenhydramine hydrochloride, lidocaine, norepinephrine, metaraminol, methylphenidate, succinylcholine, etc. Occasionally, this product may also be contraindicated with the following drugs: penicillin, methicillin, hydrocortisone succinate, phenytoin sodium. Prochlorperazine, vitamins

Keep away from light, tightly sealed, and stored in a cool, dark place.

0.1g

24 months

Hainan Rizhongtian Pharmaceutical Co., Ltd.

• Founded in:

  2002-10-23

• Address:

  Plant No. 4, Biopharmaceutical Park, Science and Technology City, Yangpu Economic Development Zone

• Tax NO.:

  91460300742566038D

• Registered Funds:

  40 million yuan

• Email:

  Log in to view